Grace Therapeutics, Inc. (GRCE) Return on equity 2022–2023
Grace Therapeutics, Inc. (GRCE) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-39.2%FY2023 · since FY2022: -17.6% → -39.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -39.2% | -21.5 pp |
| FY2022 | -17.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More GRCE financial trends
GRCE RevenueGRCE Net incomeGRCE Net marginGRCE Gross profitGRCE Gross marginGRCE Operating incomeGRCE Operating marginGRCE Operating cash flowGRCE Free cash flowGRCE Capital expendituresGRCE Stock buybacksGRCE Dividends paidGRCE Total assetsGRCE Total liabilitiesGRCE Shareholders’ equityGRCE overview →